ArticleCureus2025
An Exceptional Primary Breast Tumor: A Report of Two Mucinous Cystadenocarcinoma Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucinous cystadenocarcinoma of the breast (BMCA) is an exceptionally rare malignant tumor. Histologically, BMCA features cystic structures lined with tall columnar cells rich in intracytoplasmic and extracellular mucin, resembling mucinous cystadenocarcinomas of the ovary, pancreas, and appendix. Typically triple-negative for hormone receptors and human epidermal growth factor receptor 2 (HER2), BMCA paradoxically demonstrates a better prognosis compared to other triple-negative breast cancers. Diagnosis requires exclusion of metastatic mucinous carcinomas from other primary sites and differentiation from other mucin-producing breast tumors through a combination of clinical, radiological, histopathological, and immunohistochemical evaluations. We present two cases illustrating the variable histological features and hormone receptor status of BMCA, emphasizing differential diagnosis challenges. Given its rarity, further studies are necessary to better clarify the molecular pathogenesis of BMCA, guiding optimal management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.